Updated on: November 15, 2026 by John Ingham
Legal context: Tennessee banned kratom effective July 1, 2026. DEA issued a temporary Schedule I order for mitragynine pseudoindoxyl, MGM-15, and MGM-16 effective August 26, 2026. A separate October 14, 2026 notice proposed threshold-based controls for 7-OH and mitragynine pseudoindoxyl; a notice of intent is distinct from a final scheduling order. Earlier retail availability is not evidence that a product is currently lawful.
Key Points
- 7tabz are concentrated 7-hydroxymitragynine tablets sold through smoke shops and online markets, often using supplement-style branding.
- Concentrated 7-OH products differ from traditional kratom leaf. Uncertain contents, opioid-like effects, physical dependence, and withdrawal are concerns; reliable human data on specific brands remain limited.
- How Brooks helps: Brooks treats 7-OH tablet dependence with individualized withdrawal support, residential treatment, and recovery planning for cravings and relapse risk. Brooks also offers its Partial Hospitalization Program (PHP) for continued clinical treatment and sober living for structured recovery housing and peer support, based on individual needs.
If you have searched for 7tabz, you have probably seen the product in smoke shops, kratom stores, or online supplement retailers. The name comes up frequently in conversations about 7-hydroxymitragynine, often shortened to 7-OH, a powerful compound related to the kratom plant.
Many people assume 7tabz is just another kratom supplement. In reality, the product represents a newer category of high-potency kratom-derived alkaloid tablets that work differently from traditional kratom powder. This guide explains what the 7tabz brand is, what its tablets contain, and why healthcare professionals are increasingly discussing products like this.
7tabz at a Glance
| Category | Information |
|---|---|
| Brand name | 7tabz |
| Product type | Alkaloid extract tablets |
| Marketed ingredients | 7-Hydroxymitragynine; some versions also advertise mitragynine pseudoindoxyl |
| Advertised tablet strength | Varies by version. FDA documented 15 mg and 30 mg 7-OH products and a 20 mg 7-Hydroxy+Pseudo product; these are marketing claims, not independent content verification. |
| Packaging | Small blister packs or multi-tablet packs |
| Marketed uses | Relaxation, mood effects, and pain relief |
An FDA warning letter to 7Tabz Retail, LLC dated June 25, 2025 identifies these marketed products. It does not establish that every tablet contains the advertised amount.
What 7tabz Tablets Contain
7tabz products are marketed around 7-hydroxymitragynine, an alkaloid found in small amounts in kratom (Mitragyna speciosa). Formulations vary, and some versions also advertise mitragynine pseudoindoxyl.
However, the concentration in these products is much higher than what occurs naturally in kratom leaves. Natural kratom typically contains only trace amounts of 7-hydroxymitragynine, often under two percent of the plant’s alkaloid content.
Concentrated 7-OH products may be produced by chemically converting mitragynine rather than simply extracting naturally occurring 7-OH from leaves. Their composition and effects cannot be assumed to match traditional kratom powder or capsules, and a safe dose for these retail products has not been established.
How 7tabz Is Different From Regular Kratom
Many people first encounter kratom as:
- loose leaf powder
- capsules
- brewed tea
Traditional kratom leaf products contain a mixture of alkaloids, primarily mitragynine. Products marketed as concentrated 7-OH tablets have a different composition; some are blends rather than single-alkaloid products. Findings about traditional leaf products do not automatically apply to these tablets.
Laboratory and animal studies show that 7-hydroxymitragynine activates mu-opioid receptors and produces opioid-like effects. These findings help explain concerns about sedation, dependence, and overdose, but they do not establish a safe or effective human dose for branded tablets.
7-Hydroxymitragynine (7-OH) Delivery Methods Compared
Products marketed as containing 7-hydroxymitragynine (7-OH) come in several forms. Reliable human studies comparing the onset and duration of these retail products are lacking, so precise timing ranges would give a misleading impression of certainty.
| Delivery Method | Common Product Types | Onset Time | Duration | Absorption | Notable Considerations |
|---|---|---|---|---|---|
| Tablets / Capsules | 7tabz, Press’d | Not established for these products | Variable; reliable product-specific data are limited | Digestive system | Labeled amounts do not guarantee contents or a safe dose |
| Vapes | 7-OH cartridges or disposables | Not established for these products | Variable; reliable product-specific data are limited | Lungs (inhalation) | Inhalation safety and delivered dose are not established |
| Edibles / Chocolates | Infused chocolates, gummies | Not established for these products | Variable; reliable product-specific data are limited | Digestive system | Food-like presentation does not establish safety |
| Drinks / Shots | Bottled beverages, tonic shots | Not established for these products | Variable; reliable product-specific data are limited | Digestive system (liquid absorption) | Liquid format does not establish predictable timing |
| Extract Powders | Concentrated 7-OH powders | Not established for these products | Variable; reliable product-specific data are limited | Digestive system | High variability in dosing accuracy |
How These Forms Actually Differ
Route of use, formulation, actual contents, other substances, and individual factors may all affect exposure and risk. The cited evidence does not support a reliable fastest-to-slowest ranking of these retail products.
- Vapes/Carts introduce additional uncertainty about inhaled ingredients and delivered dose
- Drinks can differ in concentration and formulation; liquid form alone does not predict onset
- Edibles can have variable contents and absorption; their duration is not reliably established
- Tablets may state a milligram amount, but that does not independently verify contents or consistency
This is why two products with the same labeled milligram amount can feel very different depending on how they are taken.
Where “Feel Free” and Other Kava + Kratom Beverages Fit In
Products like Feel Free are often grouped into this conversation, but they are not the same thing as pure 7-OH products. Feel Free is typically described as a kava + kratom beverage, not a concentrated 7-hydroxymitragynine product. That means:
- It contains botanical extracts rather than isolated 7-OH
- Effects may come from a combination of kava (kavalactones) and kratom alkaloids
- It is usually marketed as a “functional beverage” rather than an alkaloid tablet or extract
Learn more about kava and kratom drinks like Feel Free →
Why Products Like 7tabz Are Becoming Popular
The kratom market has changed significantly in the past few years. Instead of selling only raw plant material, companies have started releasing high-potency extract products.
Products like 7tabz are marketed using claims such as:
- High potency in a small tablet
- Convenient tablet format
- Specific milligram amounts on the label
Retailers often describe them as “precision-dosed” kratom tablets designed for convenience and potency. These marketing descriptions are not proof of accuracy, safety, or therapeutic benefit.
Popular 7-OH Tablet Brands Compared
As interest in 7-hydroxymitragynine tablets has grown, several brands have appeared in smoke shops and online stores. These products can vary widely in potency, formulation, and labeling transparency.
| Brand | Product Type | Advertised Strength | Format | Notable Characteristics |
|---|---|---|---|---|
| 7tabz | 7-OH extract tablets | 15 mg and 30 mg versions documented by FDA; other formulations vary | Pressed tablets | Widely searched branded product, sold in blister packs |
| Press’d | 7-OH tablets | Varies by product; not independently verified here | Pressed tablets | Marketed as high-potency extract tablets |
| Hydroxie | 7-OH extract products | Varies | Tablets and extracts | Focus on isolated 7-hydroxymitragynine branding |
| OPiA | 7-OH tablets | Varies | Tablets | Positioned as premium alkaloid product |
| Kream | 7-OH enhanced tablets | Varies | Tablets | Often marketed alongside kratom extracts |
| 7OHM | 7-hydroxymitragynine tablets | Varies | Tablets | Brand name directly tied to compound |
| PureOHM | 7-OH products | Varies | Tablets / extracts | Focus on “purity” marketing claims |
Source: Brooks Healing Center 7-OH detox & addiction treatment center, 2026
Important Context About These Brands
These products are often marketed with supplement-style branding, but that does not establish lawful supplement status. Important limitations include:
- There is no standardized dosing across brands
- Label accuracy can vary between manufacturers
- Products may contain different forms or concentrations of 7-OH
- Tennessee bans kratom; federal rules distinguish compounds and proposed actions from effective orders
Because of that, two products labeled similarly may not produce the same effects or strength.
Regulatory Attention Around 7-OH Products
FDA has issued warning letters concerning concentrated 7-OH products. In its June 2025 letter to 7Tabz Retail, LLC, FDA identified the named products as unapproved new drugs and adulterated dietary supplements. Supplement-style packaging does not mean FDA has reviewed a product for safety or effectiveness.
State and federal actions are separate. Tennessee’s kratom ban took effect July 1, 2026. DEA’s August 26, 2026 order covered mitragynine pseudoindoxyl, MGM-15, and MGM-16. Its October 14, 2026 notice addressed proposed threshold-based controls for 7-OH and mitragynine pseudoindoxyl. That notice should not be described as an effective final order; consult the current official rules for the product and jurisdiction involved.
Potential Risks of High-Potency Alkaloid Products
Not everyone who uses kratom develops a problem. But higher-potency products like 7tabz can increase certain risks.
These may include:
- tolerance
- dependence
- withdrawal symptoms
- stronger sedation
- interactions with other substances
Because the compound activates opioid receptors, repeated use may lead to physical dependence similar to other opioid-like substances.
Why Addiction Specialists Are Paying Attention
Treatment providers across the United States are seeing a wider variety of substances than they did even a few years ago.
Instead of only encountering traditional drugs like opioids or stimulants, clinicians are now seeing:
- kratom extracts
- concentrated alkaloids
- research chemicals
- designer supplements
Products like 7tabz are high-potency compounds that may still be marketed online, but older retail availability should not be treated as proof that they are currently lawful or safe.
When to Seek Help
Some people try products like kratom or 7-OH extracts while looking for relief from pain, anxiety, or opioid withdrawal. Due to the addictive potential of products like 7Tabz, professional treatment can help stabilize symptoms and address underlying issues. Addiction treatment today includes support for traditional drugs as well as newer compounds appearing in smoke shops and online supplement markets.
Treatment Options for 7Tabz and Other Kratom-Related Substance Use
As products like 7-OH tablets and 7Tabz become more common, treatment providers are seeing more cases involving kratom extracts and concentrated alkaloids. While everyone’s situation is different, there are effective options that can help people stabilize and move forward.
Medical Detox
A clinical assessment can determine whether supervised withdrawal management or another level of care is appropriate. Not everyone requires inpatient detox. Support may address symptoms such as:
- restlessness
- anxiety
- sleep disruption
- physical discomfort
Medical support can make the process safer and more manageable, especially with higher-potency products.
Medication-Assisted Treatment (MAT)
In some cases, providers may use medications to help reduce cravings and stabilize the body. This approach is often called medication-assisted treatment (MAT).
There is no medication specifically FDA-approved to treat dependence on 7Tabz or concentrated 7-OH products. A clinician may consider medications used for opioid use disorder when clinically appropriate, but evidence for treating 7-OH-related problems is limited and treatment must be individualized. Receptor activity alone is not enough to choose a medication or level of care.
The goal is not just symptom relief, but helping people regain stability and reduce the risk of relapse.
Residential Treatment
Residential or inpatient treatment provides a more structured environment for people who need time away from triggers or daily stressors.
These programs typically include:
- individual therapy
- group support
- mental health care
- relapse prevention planning
For people dealing with both substance use and mental health challenges, this level of care can provide a more complete reset and support system.
Frequently Asked Questions About 7Tabz
What is 7tabz?
7tabz is a branded tablet product that contains 7-hydroxymitragynine (7-OH), a potent alkaloid derived from the kratom plant (Mitragyna speciosa). These products are marketed as concentrated 7-OH tablets, and some versions also advertise other compounds. Label claims do not independently establish the contents, safety, or effects of a particular tablet.
What is 7tabz used for?
People who buy 7tabz often report using it for relaxation, pain relief, mood changes, or sedation. Because 7-hydroxymitragynine interacts with opioid receptors in the brain, it can produce effects similar to opioid medications. Some users also experiment with it as an alternative to kratom extracts or other kratom-based supplements.
What are 7Tabz pills?
7tabz tablets are kratom-derived alkaloid tablets containing 7-hydroxymitragynine extract. These pills are typically sold in small blister packs or multi-tablet packages and are marketed as high-potency kratom-related products.
Can you snort 7tabz?
7tabz tablets are designed to be taken orally, and altering how a substance is used can increase health risks. Crushing or snorting tablets can expose the body to unpredictable doses and may irritate nasal tissue or increase the likelihood of adverse reactions.
How long does 7tabz last?
Reliable product-specific human data do not establish a predictable onset or duration for 7tabz. Effects may vary with the actual contents, amount used, formulation, other substances, tolerance, and individual factors. Timing estimates from user reports should not be treated as a safe dosing guide.
Sources
- Kruegel, A. C., Uprety, R., Grinnell, S. G., Langreck, C., Pekarskaya, E. A., Le Rouzic, V., Ansonoff, M., Gassaway, M. M., Pintar, J. E., Pasternak, G. W., Javitch, J. A., Majumdar, S., & Sames, D. (2019). 7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects. ACS Central Science, 5(6), 992–1001. https://doi.org/10.1021/acscentsci.9b00141
- Hemby, S. E., McIntosh, S., Leon, F., Cutler, S. J., & McCurdy, C. R. (2019). Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addiction Biology, 24(5), 874–885. https://doi.org/10.1111/adb.12639
- Obeng, S., Wilkerson, J. L., León, F., Reeves, M. E., Restrepo, L. F., Gamez-Jimenez, L. R., Patel, A., Pennington, A. E., Taylor, V. A., Ho, N. P., Braun, T., Fortner, J. D., Crowley, M. L., Williamson, M. R., Pallares, V. L. C., Mottinelli, M., Lopera-Londoño, C., McCurdy, C. R., McMahon, L. R., & Hiranita, T. (2021). Pharmacological comparison of mitragynine and 7-hydroxymitragynine: In vitro affinity and efficacy for μ-opioid receptor and opioid-like behavioral effects in rats. Journal of Pharmacology and Experimental Therapeutics, 376(3), 410–427. https://doi.org/10.1124/jpet.120.000189
- Reissig, C. J., Chiapperino, D., Seitz, A., Lee, R., Radin, R., & McAninch, J. (2025). 7-Hydroxymitragynine (7-OH): An assessment of the scientific data and toxicological concerns around an emerging opioid threat. U.S. Food and Drug Administration. https://www.fda.gov/files/drugs/published/7-hydroxymitragynin_7-oh_an_assessment_of_the_scientific_data_and_toxicological_concerns_around_an_emerging_opioid_threat.pdf
- U.S. Food and Drug Administration. (n.d.). FDA and kratom. https://www.fda.gov/news-events/public-health-focus/fda-and-kratom
- U.S. Food and Drug Administration. (2025, June 25). 7Tabz Retail, LLC (MARCS-CMS 709546) [Warning letter]. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/7tabz-retail-llc-709546-06252025
- Henningfield, J. E., Chawarski, M. C., Garcia-Romeu, A., Grundmann, O., Harun, N., Hassan, Z., McCurdy, C. R., McMahon, L. R., Sharma, A., Shoaib, M., Singh, D., Smith, K. E., Swogger, M. T., Vicknasingam, B., Walsh, Z., Wang, D. W., & Huestis, M. A. (2023). Kratom withdrawal: Discussions and conclusions of a scientific expert forum. Drug and Alcohol Dependence Reports, 7, 100142. https://doi.org/10.1016/j.dadr.2023.100142
- Anderer, S. (2025). What to know about 7-OH, the new vape shop hazard. JAMA, 334(12), 1045–1046. https://doi.org/10.1001/jama.2025.13592
Drug Enforcement Administration. (2026, July 1). DEA to temporarily schedule 7-OH and related substances to protect the public. https://www.dea.gov/press-releases/2026/07/01/dea-temporarily-schedule-7-oh-and-related-substances-protect-public.
Tennessee Department of Mental Health and Substance Abuse Services. (2026). Emerging substances: Kratom. https://www.tn.gov/behavioral-health/substance-abuse-services/prevention/emerging-substances.html.
Drug Enforcement Administration. (2026, August 26). Schedules of controlled substances: Temporary placement of mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I. Federal Register, 91, 54948–54956. https://www.govinfo.gov/content/pkg/FR-2026-08-26/html/2026-17429.htm
Drug Enforcement Administration. (2026, October 14). Schedules of controlled substances: Temporary placement of 7-hydroxymitragynine and mitragynine pseudoindoxyl above a specified threshold in Schedule I [Notice of intent]. Federal Register, 91, 65370–65381. https://www.govinfo.gov/content/pkg/FR-2026-10-14/html/2026-20943.htm